Immunai announces collaboration with AstraZeneca for advanced clinical trial optimization

• Immunai, a leading artificial intelligence (AI) biotech company, has pioneered AMICA™, its proprietary immune cell atlas, with multi-omic single-cell resolution combined with its AI model of the immune system, the Immunodynamics Engine (IDE)™
• Under the collaboration, AstraZeneca will leverage Immunai’s proprietary platform and machine learning capabilities to inform certain oncology clinical trials​
• This multi-year collaboration builds on Immunai’s earlier work with AstraZeneca, which began in 2022 and provided insights for multiple clinical programs

Immunai Inc., a NY-based artificial intelligence and biotech company, mapping the human immune system with single-cell granularity, has announced a multi-year collaboration with AstraZeneca. Under the terms of the agreement, Immunai is set to receive $18M for the initial phase of the collaboration. The collaboration will focus on clinical decision-making, including dose selection, elucidating mechanisms of action, patient responder vs. non-responder analysis, and biomarker identification, by leveraging Immunai’s AI model of the immune system, the IDE™. This collaboration aims to improve the success rates of ongoing clinical trials to maximize research and development productivity. After this initial phase, AstraZeneca has an option to expand the length and scope of the collaboration.​

“This collaboration is a natural progression of our successful work in advancing drug development in the fields of oncology and immunology,” said Noam Solomon, Ph.D., CEO of Immunai. “Bringing a drug to market is incredibly challenging, time consuming and expensive. Through this collaboration with AstraZeneca, we’re excited to leverage our AI-based engine the IDE™ to help make this process more efficient in bringing potential new therapies to patients.”

“Artificial Intelligence is transforming cancer drug discovery and clinical development. We are very pleased to collaborate with Immunai to leverage their innovative platform to enhance our data-driven R&D strategy and glean potential new insights into mechanisms of action of immunotherapies,” said Iker Huerga, Chief Data Scientist, Oncology R&D, AstraZeneca.

For more information on partnering with Immunai, please visit immunai.com.

About Immunai:
Immunai uses single-cell genomics and machine learning to discover and improve development of novel therapeutics by decoding the immune system. The team of 170 employees, 85 of whom are PhDs or MDs, is composed of experts in genomics, machine learning, bioinformatics, immunology, and software engineering. The company has more than 30 partnerships with Fortune 100 pharmaceutical companies and leading academic institutions. Headquartered in New York City, with offices in Tel Aviv, Zurich, Prague, the company has raised close to $270M in funding to-date. For more information visit www.immunai.com.

Contact Information

Jennifer Henry

PR for Immunai

VSC for Immunai

Contact via E-mail